Cognitive disorders

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

Retrieved on: 
Thursday, July 8, 2021
Psychiatry, Cognitive disorders, Psychiatric diagnosis, Health, Learning disabilities, Alzheimer's disease, Aging-associated diseases, Biogen, Mild cognitive impairment, Dementia, Clinical trial, Donepezil

Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • The update clarifies the indication by emphasizing information about the disease stages studied in the ADUHELM clinical trials.
  • Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies statement of June 23, 2021.
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation

Retrieved on: 
Wednesday, July 7, 2021
Psychiatry, Branches of biology, Neuroscience, Cognitive disorders, Psychiatric diagnosis, Learning disabilities, Aphasias, Dementia, Antipsychotic, Alzheimer's disease, Psychosis

Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.

Key Points: 
  • Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.
  • Right now, the most common medical treatment for agitation associated with Alzheimer's is off-label use of antipsychotic drugs, which typically provide only marginal improvement, often with undesirable side effects.
  • AD is an irreversible neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Mediaplanet Partners With Seth Rogen and Lauren Miller Rogen to Advocate for Better Senior Health and Care

Retrieved on: 
Tuesday, July 6, 2021
Aging-associated diseases, Actors, Medicine, Medical specialties, Psychiatric diagnosis, Seth Rogen, Rogen, Cognitive disorders, Geriatrics, Dementia, Parkinson's disease, Chronic condition

Some of the most common health problems in the elderly include: dementia and Alzheimer's, Parkinson's, osteoporosis, depression, and balance issues.

Key Points: 
  • Some of the most common health problems in the elderly include: dementia and Alzheimer's, Parkinson's, osteoporosis, depression, and balance issues.
  • Furthermore, at any given time, over 65 million people are providing care for a chronically ill, disabled, and/or senior family member or friend.
  • Comedian and actor Seth Rogen, and screenwriter, actress, and director Lauren Miller Rogen, grace the cover of the print publication.
  • From that moment on, Seth and Lauren have used their platforms to raise awareness for the disease and inspire others to do the same.

Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease

Retrieved on: 
Tuesday, July 6, 2021
Health sciences, Health, Clinical research, Medicine, Design of experiments, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Placebo-controlled study, Clinical trial, Placebo

The data we will continue to collect in this open label extension could help us to better understand the long-term safety and efficacy profile of ATH-1017 and could help Athira best design future clinical trials of ATH-1017.

Key Points: 
  • The data we will continue to collect in this open label extension could help us to better understand the long-term safety and efficacy profile of ATH-1017 and could help Athira best design future clinical trials of ATH-1017.
  • The randomized, double-blind, placebo-controlled trials are evaluating the safety and efficacy of ATH-1017 in mild-to-moderate Alzheimers disease.
  • Patients in both trials are being evaluated for improvement in cognition, global and functional assessments comparing treatment arms to placebo.
  • In addition to Alzheimers disease, ATH-1017 is designed to address the broader dementia population, including Parkinsons disease dementia.

Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) (Central Nervous System) Drugs in Development, 2021 Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
General Health, Pharmaceutical, Health, Other Health, Cognitive disorders, Neurodegenerative disorders, Corticobasal syndrome, Rare diseases, Corticobasal degeneration, Basal ganglia, CBD, Branches of biology, Neuroscience, Academic disciplines

The "Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The report assesses Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) (Central Nervous System) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Belmont Village Senior Living Shares Six Tips to Mitigate Cognitive Decline Without Meds

Retrieved on: 
Wednesday, June 30, 2021
Other Health, Managed care, Family, Consumer, Mental health, Residential Building & Real Estate, Hospitals, Construction & Property, Fitness & Nutrition, Nursing, Seniors, Health, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Branches of biology, Neuroscience, Dementia, Alzheimer's disease, Belmont

With an estimated 6.2 million Americans age 65+ living with Alzheimer's disease , many families struggle to slow cognitive decline in loved ones.

Key Points: 
  • With an estimated 6.2 million Americans age 65+ living with Alzheimer's disease , many families struggle to slow cognitive decline in loved ones.
  • Belmont Village Senior Living shares six lifestyle tips that when applied systematically and under the guidance of trained professionals, can help alter cognitive decline.
  • More and more, things are forgotten or misplaced, says Patricia Will, founder & CEO of Belmont Village Senior Living.
  • Each is still a human being with a spirit that must be kept alive, relevant, and hopeful, says Beverly Sanborn, VP of Program Development at Belmont Village Senior Living.

New Research Reveals SafelyYou's AI-Enabled Fall Detection Reduces Time on the Ground After a Resident Falls in Memory Care Facility

Retrieved on: 
Wednesday, June 30, 2021
Cognitive disorders, Psychiatric diagnosis, Health, Psychiatry, Dementia, Emergency department, Medicine

"Congratulations to the SafelyYou team for changing and improving the quality of care for people living with dementia."

Key Points: 
  • "Congratulations to the SafelyYou team for changing and improving the quality of care for people living with dementia."
  • The study was conducted in six memory care facilities in California, where SafelyYou's cameras were installed in bedrooms of consenting residents and families.
  • Reducing time on the ground has the potential to decrease future morbidity, unnecessary emergency room visits and related health care costs."
  • To learn more about reducing time on the ground or developing a fall management program for memory care, contact [email protected] .

Watercrest Newnan Assisted Living and Memory Care Supports the Alzheimer's Association's Longest Day Initiative

Retrieved on: 
Tuesday, June 29, 2021
Health, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Alzheimer's Association, Assisted living, Dementia, Alzheimer's disease

VERO BEACH, Fla., June 29, 2021 /PRNewswire/ --Residents, associates, and community members gathered last weekend for a classic car show at Watercrest Newnan Assisted Living and Memory Care to support the Alzheimer's Association's global initiative, 'The Longest Day.'

Key Points: 
  • VERO BEACH, Fla., June 29, 2021 /PRNewswire/ --Residents, associates, and community members gathered last weekend for a classic car show at Watercrest Newnan Assisted Living and Memory Care to support the Alzheimer's Association's global initiative, 'The Longest Day.'
  • The longest day of the year is the day with the most light, therefore 'The Longest Day' initiative symbolizes the unity of participants to fight the darkness of Alzheimer's through various activities and fundraising events.
  • Watercrest Newnan is a 92,000 square-foot, signature Watercrest product offering 75 assisted living and 32 memory care apartments with premium accommodations, resort-style amenities, and world-class care.
  • Watercrest senior living communities are recognized for their luxury aesthetic, exceptional amenities and world-class care, including unparalleled service to seniors living with Alzheimer's and dementia.

Global Cognitive Assessment and Training Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021
Mental health, Health, Cognitive disorders, Mind, Cognition, Thought, Cognitive deficit, Pediatrics, Special education, g factor

The "Cognitive Assessment and Training Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cognitive Assessment and Training Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global cognitive assessment and training market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global cognitive assessment and training market to grow at a CAGR of around 22% during the forecast period (2021-2026).
  • Cognitive assessment and training solutions are used for detecting the signs of cognitive impairment in the early stages.

Infinity BiologiX and Cytox Collaborate to Provide New Genetic Test to Predict the Risk of Cognitive Decline Due to Alzheimer’s Disease

Retrieved on: 
Wednesday, June 23, 2021
Health, Genetics, General Health, Clinical trials, Research, Science, Biotechnology, Medicine, Branches of biology, Clinical medicine, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Medical genetics, Medical tests, Genetic testing, Alzheimer's disease, Disease, Dementia, Infinity BiologiX (IBX):, Cytox, genoSCORE™, INFINITY BIOLOGIX (IBX):, CYTOX, GENOSCORE™

Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.

Key Points: 
  • Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.
  • Dr. Richard Pither, CEO of Cytox, commented: Alzheimers disease affects over 46 million people in the world1.
  • genoSCORE is a new non-invasive, genetic test to predict future risk of cognitive decline due to Alzheimers disease (AD).
  • This test is a measure of relative risk for future onset of Late-onset Alzheimers disease (LOAD) and should not be considered as standalone diagnostic test.